ENTEROEntero Healthcare Solutions Ltd.
Entero Healthcare Solutions Q2 FY27 Results: Consolidated Net Profit ₹60.74 Crore on Total Income of ₹2,091 Crore
- Earnings
- pharmaceutical distribution
Reviewed byKeshav SehgalBlacklitt Research
Entero Healthcare Solutions (NSE: ENTERO) reported consolidated total income of ₹2,091.07 crore and net profit of ₹60.74 crore for the quarter ended 30 Sep 2026, it said in a filing on 04 Nov 2026. Standalone total income was ₹136.65 crore and standalone net profit was ₹19.14 crore for the same quarter.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹2,091.07 crore, up 32.7% YoY and 7.6% QoQ
- Net profit: ₹60.74 crore, up 66.0% YoY and 16.7% QoQ; ₹45.54 crore attributable to owners
- EPS: ₹10.47 basic, up 44.2% YoY from ₹7.26
- Finance costs: ₹23.14 crore, up 86.6% YoY from ₹12.40 crore
Standalone
The company on its own, without its subsidiaries
- Total income: ₹136.65 crore, up 27.2% YoY and 28.4% QoQ
- Net profit: ₹19.14 crore, up 236.1% YoY from ₹5.70 crore
- EPS: ₹4.40 basic, up from ₹1.31 a year earlier
- Other income: ₹22.08 crore, down 8.8% YoY, 16.2% of total income
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 2,091.07 | 1,575.74 | +32.7% | 1,943.50 | +7.6% | |
| Revenue from operations | 2,087.08 | 1,570.95 | +32.9% | 1,940.50 | +7.6% |
| Other income | 3.99 | 4.79 | -16.7% | 3.01 | +32.8% |
| 60.74 | 36.60 | +66.0% | 52.05 | +16.7% | |
| Profit before tax | 78.39 | 44.63 | +75.7% | 67.12 | +16.8% |
| Finance costs | 23.14 | 12.40 | +86.6% | 20.57 | +12.5% |
| Depreciation | 13.13 | 9.83 | +33.5% | 12.30 | +6.7% |
| Tax expense | 17.64 | 8.03 | +119.9% | 15.07 | +17.1% |
| Net profit margin | 2.90% | 2.32% | +0.58 pp | 2.68% | +0.23 pp |
| EPS, basic (₹) | 10.47 | 7.26 | +44.2% | 8.77 | +19.4% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Profit grew faster than income this quarter. Consolidated net profit rose 66.0% YoY while total income rose 32.7%, and tax expense rose 119.9% to ₹17.64 crore, so the profit before tax rise of 75.7% was partly absorbed by tax.
Finance costs rose 86.6% YoY to ₹23.14 crore, which is 1.1% of total income. The filing says the consolidated figures include six acquired entities from their share transfer dates and are not comparable with the corresponding comparative period, so the year-on-year comparison includes businesses not in the year-earlier quarter.
Other income is a small part of the consolidated result: ₹3.99 crore, or 5.1% of profit before tax of ₹78.39 crore. Revenue from operations, at ₹2,087.08 crore, makes up almost all of total income.
Consolidated net profit attributable to owners was ₹45.54 crore, against ₹60.74 crore for the period before minority interests, a gap of ₹15.20 crore that the filing attributes to non-controlling interests.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 136.65 | 107.45 | +27.2% | 106.41 | +28.4% | |
| Revenue from operations | 114.57 | 83.22 | +37.7% | 83.27 | +37.6% |
| Other income | 22.08 | 24.23 | -8.8% | 23.14 | -4.6% |
| 19.14 | 5.70 | +236.1% | 3.46 | +453.8% | |
| Profit before tax | 24.32 | 7.61 | +219.6% | 4.60 | +428.1% |
| Finance costs | 0.61 | 0.71 | -14.1% | 5.74 | -89.4% |
| Depreciation | 3.17 | 3.32 | -4.5% | 3.11 | +2.1% |
| Tax expense | 5.18 | 1.91 | +170.5% | 1.15 | +350.8% |
| Net profit margin | 14.01% | 5.30% | +8.71 pp | 3.25% | +10.76 pp |
| EPS, basic (₹) | 4.40 | 1.31 | +235.9% | 0.79 | +457.0% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone net profit rose 236.1% YoY to ₹19.14 crore, faster than standalone total income, which rose 27.2%. Revenue from operations grew 37.7% to ₹114.57 crore, while other income fell 8.8% to ₹22.08 crore.
Standalone finance costs were ₹0.61 crore, 14.1% below the year-earlier quarter and 0.4% of total income. Standalone other income of ₹22.08 crore equals 90.8% of standalone profit before tax of ₹24.32 crore, so other income is a large share of the standalone pre-tax profit.
The standalone exceptional items are shown as nil for the quarter, and tax expense of ₹5.18 crore is 21.3% of profit before tax.
Inference
The filing says the board approved the results on 4 Nov 2026 and that the auditors issued unmodified conclusions on both sets of results. The company operates in one business segment, trading of pharmaceutical and surgical products.
The company granted 49,712 employee stock options under the Entero Employee Stock Option Plan 2023 at an exercise price of INR 804 per option, and allotted 12,135 equity shares on exercise of earlier options. After the quarter, it subscribed to 15,00,000 Optionally Convertible Debentures of Chhabra Healthcare Solution Private Limited at ₹120 each.
The filing does not state the reason for the sharp rise in consolidated revenue and finance costs, the reason for the fall in standalone other income, the effect of the Sai Pharma slump sale on future results, or the price and financial effect of the Chhabra OCD subscription.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
